T-cell acute lymphoblastic leukemia

T-cell acute lymphoblastic leukemia (T-ALL) is a subtype of acute lymphoblastic leukemia (ALL), a cancer of the white blood cells. T-ALL affects T cells, a type of lymphocyte that plays a key role in the immune response.

Epidemiology

T-ALL accounts for approximately 15% of ALL cases in children and 25% in adults. It is more common in males than in females, and its incidence peaks in adolescence.

Pathophysiology

T-ALL is characterized by the malignant transformation and proliferation of immature T cells, or T lymphoblasts. This is often associated with genetic abnormalities, such as translocations and mutations, that disrupt normal T cell development.

Clinical presentation

Patients with T-ALL typically present with signs and symptoms of bone marrow failure, such as fatigue, pallor, and bleeding, as well as lymphadenopathy, hepatosplenomegaly, and sometimes mediastinal mass.

Diagnosis

The diagnosis of T-ALL is based on the morphological, immunophenotypic, and genetic analysis of peripheral blood and bone marrow samples. The presence of T lymphoblasts in these samples is indicative of T-ALL.

Treatment

The treatment of T-ALL involves intensive chemotherapy, often followed by stem cell transplantation in high-risk cases. Despite advances in treatment, the prognosis of T-ALL remains poor, particularly in adults.

Prognosis

The prognosis of T-ALL is generally worse than that of B-cell ALL, with lower rates of complete remission and higher rates of relapse. However, recent advances in treatment have improved the prognosis of T-ALL, particularly in children.

See also

• Acute lymphoblastic leukemia
• T cell
• Lymphocyte
• Chemotherapy
• Stem cell transplantation

This article is a medical stub. You can help WikiMD by expanding it!
Most recent articles Ongoing trials	Wikipedia